Literature DB >> 24061694

Review on novel concepts of columnar lined esophagus.

Johannes Lenglinger1, Stephanie Fischer See, Lukas Beller, Enrico P Cosentini, Reza Asari, Fritz Wrba, Martin Riegler, Sebastian F Schoppmann.   

Abstract

BACKGROUND: Columnar lined esophagus (CLE) is a marker for gastroesophageal reflux and associates with an increased cancer risk among those with Barrett's esophagus. Recent studies fostered the development of integrated CLE concepts.
METHODS: Using PubMed, we conducted a review of studies on novel histopathological concepts of nondysplastic CLE.
RESULTS: Two histopathological concepts-the squamo-oxyntic gap (SOG) and the dilated distal esophagus (DDE), currently model our novel understanding of CLE. As a consequence of reflux, SOG interposes between the squamous lined esophagus and the oxyntic mucosa of the proximal stomach. Thus the SOG describes the histopathology of CLE within the tubular esophagus and the DDE, which is known to develop at the cost of a shortened lower esophageal sphincter and foster increased acid gastric reflux. Histopathological studies of the lower end of the esophagus indicate, that the DDE is reflux damaged, dilated, gastric type folds forming esophagus and cannot be differentiated from proximal stomach by endoscopy. While the endoscopically visible squamocolumnar junction (SCJ) defines the proximal limit of the SOG, the assessment of the distal limit requires the histopathology of measured multilevel biopsies. Within the SOG, CLE types distribute along a distinct zonation with intestinal metaplasia (IM; Barrett's esophagus) and/or cardiac mucosa (CM) at the SCJ and oxyntocardiac mucosa (OCM) within the distal portion of the SOG. The zonation follows the pH-gradient across the distal esophagus. Diagnosis of SOG and DDE includes endoscopy, histopathology of measured multi-level biopsies from the distal esophagus, function, and radiologic tests. CM and OCM do not require treatment and are surveilled in 5 year intervals, unless they associate with life quality impairing symptoms, which demand medical or surgical therapy. In the presence of an increased cancer risk profile, it is justified to consider radiofrequency ablation (RFA) of IM within clinical studies in order to prevent the progression to dysplasia and cancer. Dysplasia justifies RFA ± endoscopic resection.
CONCLUSIONS: SOG and DDE represent novel concepts fusing the morphological and functional aspects of CLE. Future studies should examine the impact of SOG and DDE for monitoring and management of gastroesophageal reflux disease (GERD).

Entities:  

Mesh:

Year:  2013        PMID: 24061694     DOI: 10.1007/s00508-013-0418-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  114 in total

1.  Histopathology of columnar-lined esophagus in patients with gastroesophageal reflux disease.

Authors:  Johannes Lenglinger; Claudia Ringhofer; Margit Eisler; Roland Sedivy; Fritz Wrba; Johannes Zacherl; Enrico P Cosentini; Gerhard Prager; Michael Haefner; Martin Riegler
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

2.  Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas.

Authors:  Parakrama Chandrasoma; Kumari Wickramasinghe; Yanling Ma; Tom DeMeester
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

3.  Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease.

Authors:  E Savarino; L Gemignani; D Pohl; P Zentilin; P Dulbecco; L Assandri; E Marabotto; D Bonfanti; S Inferrera; V Fazio; A Malesci; R Tutuian; V Savarino
Journal:  Aliment Pharmacol Ther       Date:  2011-06-14       Impact factor: 8.171

4.  Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Authors:  M Sikkema; C W N Looman; E W Steyerberg; M Kerkhof; F Kastelein; H van Dekken; A J van Vuuren; W A Bode; H van der Valk; R J T Ouwendijk; R Giard; W Lesterhuis; R Heinhuis; E C Klinkenberg; G A Meijer; F ter Borg; J W Arends; J J Kolkman; J van Baarlen; R A de Vries; A H Mulder; A J P van Tilburg; G J A Offerhaus; F J W ten Kate; J G Kusters; E J Kuipers; P D Siersema
Journal:  Am J Gastroenterol       Date:  2011-05-17       Impact factor: 10.864

5.  Evidence-based appraisal in laparoscopic Nissen and Toupet fundoplications for gastroesophageal reflux disease.

Authors:  Cheng-Xiang Shan; Wei Zhang; Xiang-Min Zheng; Dao-Zhen Jiang; Sheng Liu; Ming Qiu
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 6.  The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus.

Authors:  David E Fleischer; Robert Odze; Bergein F Overholt; John Carroll; Kenneth J Chang; Ananya Das; John Goldblum; Daniel Miller; Charles J Lightdale; Jeffrey Peters; Richard Rothstein; Virender K Sharma; Daniel Smith; Victor Velanovich; Herbert Wolfsen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2010-04-20       Impact factor: 3.199

7.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

8.  Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells.

Authors:  Francesca Milano; Jantine W P M van Baal; Navtej S Buttar; Agnieszka M Rygiel; Floor de Kort; Cathrine J DeMars; Wilda D Rosmolen; Jacques J G H M Bergman; Jan VAn Marle; Kenneth K Wang; Maikel P Peppelenbosch; Kausilia K Krishnadath
Journal:  Gastroenterology       Date:  2007-03-19       Impact factor: 22.682

9.  The gastroesophageal flap valve: in vitro and in vivo observations.

Authors:  L D Hill; R A Kozarek; S J Kraemer; R W Aye; C D Mercer; D E Low; C E Pope
Journal:  Gastrointest Endosc       Date:  1996-11       Impact factor: 9.427

Review 10.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.